Health Care · Pharmaceutical Preparations

CRMD CorMedix Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1410098125 filings
Russell 2000

CRMD at a glance

CorMedix Inc. (CRMD, SEC CIK 1410098) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), CorMedix Inc. (CRMD) reported revenue of $311.7 million (up 617.0% from FY2024) and net income of $163.1 million. Diluted EPS was $2.04.
  • As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding CorMedix Inc. (CRMD) shares worth $139.8 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Blum Susan on November 19, 2026 of 5,000 shares at $4.58 per share.
  • In the last 90 days, CRMD insiders reported 4 open-market purchases ($588K) and 0 open-market sales ($0) on Form 4, a net purchase of $588K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$311.7M
+617.0% vs prior year
Insiders · 90 days
4 buys · 0 sells
Net +$588K
13F holders
30 funds
$139.8M · +2 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Acquisition risk: Heron transaction may fail closing conditions or stockholder vote, pressuring share price and results
  • Regulatory risk: CMS post-TDAPA adjustment reduced DefenCath net pricing in 2H 2026
  • Reimbursement risk: Quarterly CMS calculations begin in 2027, increasing DefenCath revenue volatility
  • Financial risk: Proposed $150 million senior secured term loan would increase interest costs and repayment obligations
  • Dilution risk: Heron would receive 14,583,333 shares, representing approximately 18.3% pro forma ownership

Management Discussion & Analysis

  • Revenue $54.5M, down 48% YoY from $104.3M, driven by lower DefenCath net pricing
  • Gross margin 55.0% vs 89.3% YoY, with net income $14.7M loss vs $108.6M income
  • DefenCath worst performer, product sales $17.2M vs $88.8M; Melinta Portfolio sales $31.4M vs $12.8M
  • Cash and investments $355.2M vs $148.5M at December 31, 2025; operating cash flow $218.3M year to date
  • CMS reimbursement headwind: $8.32 add-on effective January 2027, expected 2027 average at least twice $2.37 current rate

AI summary of the CRMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Conference call discussed CorMedix’s financial results for quarter ended September 30, 2026
  • Full investor-call transcript furnished as Exhibit 99.1, containing management commentary and financial-results details

Item EX-99.1: Item EX-99.1

  • Q3 revenue $54.5M, down from $104.3M, reflecting DefenCath pricing pressure after post-TDAPA transition
  • DefenCath sales $17.2M, with dialysis utilization largely maintained at the $2.37 add-on rate
Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • CorMedix announced financial results for the quarter ended September 30, 2026
  • Investor-relevant figures and management commentary are contained in Exhibit 99.1, the accompanying earnings release

Item EX-99.1: Item EX-99.1

  • Q3 revenue $54.5M, down from $104.3M, reflecting DefenCath pricing pressure after post-TDAPA transition
  • DefenCath revenue $17.2M, including a $5.0M favorable sales-allowance estimate change, signaling underlying pricing sensitivity
Filed Nov 10, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Proposed acquisition of substantially all Heron assets, adding four FDA-approved commercial brands to CorMedix’s portfolio
  • Transaction expected to diversify revenue, generate synergies and be earnings accretive, subject to closing conditions

Item EX-99.2: Item EX-99.2

  • Proposed asset acquisition adds four FDA-approved brands, including ZYNRELEF, APONVIE, CINVANTI and SUSTOL
  • Upfront consideration: $145 million cash plus 14,583,333 CorMedix shares valued at $7.20 each

Item EX-99.1: Item EX-99.1

  • Heron acquisition adds 4 commercial products and approximately $150 million in trailing 12-month net product revenue
  • Upfront consideration: $145 million cash plus approximately 14.6 million CorMedix shares, valued at approximately $77.6 million at $5.32

AI summaries of CRMD 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CRMD

Don't miss the next CRMD filing

  • Alerts as it files. A push when CRMD files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CRMD, by share count.
  • Ask anything. An AI agent that reads every CRMD filing and answers with sources.

CRMD alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Blum SusanBuyNov 19, 2026$4.58
Lefkowitz Steven WBuyNov 18, 2026$4.53
Kaplan MyronBuyNov 16, 2026$4.88
Todisco JosephBuyNov 13, 2026$4.89
Dillione JanetMSep 18, 2026-
Dillione JanetMSep 18, 2026-
Zelnick Kaufman BethFAug 29, 2026$8.30
Blum SusanFAug 29, 2026$8.30

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$43.5M$311.7M
Gross Profit-$40.3M$275.7M
Operating Income--$22.4M$150.1M
Net Income--$17.9M$163.1M
Gross Margin-92.7%88.5%
Op. Margin--51.4%48.2%
Net Margin--41.2%52.3%
Balance Sheet
Total Assets$82.1M$118.8M$826.1M
Equity-$84.7M$405.3M
ROE--21.2%40.2%
Per Share
EPS-$-0.30$2.04
Cash Flow
Operating CF--$50.6M$175.0M
CapEx$327K$116K$2.3M

Source: XBRL data in CorMedix Inc. (CRMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CRMD share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CRMD shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202630$139.8M
Q2 202628$128.8M
Q1 202626$107.2M
Q4 202525$201.8M
Q3 202525$213.2M
Q2 202526$207.5M
Q1 202522$53.6M
Q4 202419$57.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 201 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CRMD filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 18, 2026--
4Nov 16, 2026--
8-KNov 16, 2026Analysis-
10-QNov 12, 2026Analysis
8-KNov 12, 2026Analysis-
8-KNov 10, 2026Analysis-
8-KNov 9, 2026Analysis-
8-KNov 2, 2026Analysis-
8-KOct 19, 2026Analysis-
4Sep 18, 2026--
4Sep 1, 2026--
4Sep 1, 2026--
4Sep 1, 2026--
10-QAug 13, 2026Analysis
8-KAug 13, 2026Analysis-
8-KAug 7, 2026Analysis-
8-KJul 2, 2026Analysis-
8-KJul 1, 2026Analysis-
8-KJun 24, 2026Analysis-
8-KJun 8, 2026Analysis
10-QMay 14, 2026Analysis
8-KMay 14, 2026-
8-KApr 27, 2026--

Related Health Care companies

All Health Care →

CRMD SEC filings: frequently asked questions

Are CRMD insiders buying or selling?

In the last 90 days, CorMedix Inc. (CRMD) officers, directors and 10% owners reported 4 open-market purchases worth $588,195 by 4 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CRMD stock?

As of September 30, 2026, the largest CorMedix Inc. (CRMD) holders among the 13F filers tracked by SignalX were BlackRock ($49.7 million), Vanguard Capital Management LLC ($23.5 million), State Street Corp ($20.3 million), Goldman Sachs Group ($9.6 million), Vanguard Portfolio Management LLC ($5.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CRMD's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), CorMedix Inc. (CRMD) reported revenue of $311.7 million (up 617.0% from FY2024) and net income of $163.1 million. Diluted EPS was $2.04. The figures come from the XBRL data in the 10-K.

What did CRMD report in its latest 8-K?

CorMedix Inc. (CRMD) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure). Conference call discussed CorMedix’s financial results for quarter ended September 30, 2026.

What are the latest CRMD SEC filings?

CorMedix Inc. (CRMD) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 20, 2026.

What is CRMD's SEC CIK number?

CorMedix Inc. (CRMD)'s SEC Central Index Key (CIK) is 1410098. EDGAR lists every CRMD filing under that number.

Ask anything about CRMD

The research agent reads CRMD's filings, financials, insider trades and 13F holders, then answers with sources.